Idogen publishes interim report for 1 January – 30 June 2022

Idogen AB's interim report for January to June 2022 is available on the company's website https://idogen.com/en/investors/financial-reports/

Second quarter (April-June 2022)

• Other operating income amounted to KSEK 159 (1,731)

• Operating loss was KSEK -11,157 (-9 541)

• Loss for the quarter totalled KSEK -11,196 (-9,604)

• Cash flow from operating activities was KSEK -10,172 (-6,135)

• Loss per share before dilution was SEK -0.15 (-0.53). Loss per share after dilution was SEK -0.15 (-0.53)

Period (January-June 2022)

• Other operating income amounted to KSEK 159 (3,409)

• Operating loss was KSEK -21,869 (-20,164)

• Loss for the quarter totalled KSEK -21,888 (-20,135)

• Cash flow from operating activities was KSEK -28,232 (-16,087)

• Loss per share before dilution was SEK -0.38 (-1,10). Loss per share after dilution was SEK -0.38 (-1,10)

Significant events in the second quarter

• Idogen receives approval from the Norwegian Medicines Agency, NoMA, for a clinical phase 1/2a study

with the IDO 8 program.

• Idogen strengthens the organization with key competencies for the clinical development phase.

Significant events in the period

• Idogen submits an application for clinical trial with IDO 8 to the Norwegian Medicines Agency, NoMA.

• Idogens presented the company’s tolerogenic cell therapy platform at the 5th Antigen-Specific Immune Tolerance Summit.

• Idogen enters into an agreement with Vator Securities AB regarding the assignment as Certified Adviser from 15 May.

 • Idogen’s rights issue raise MSEK 41 after issue costs.

• Idogen receives approval from the Swedish Medical Products Agency to start its clinical phase 1/2a study for IDO 8.

Significant events after the end of the period

• Idogen brings together scientific advisors at the ISTH 2022 scientific conference in London.

• Idogen's CEO Anders Karlsson leaves for a new assignment and Christina Herder is appointed acting CEO

• Idogen convene major owners for election to Board

• Idogen invite to an Extraordinary General Shareholder Meeting on September 6

 • No other significant events occurred after the end of the period that affected the results or financial position.

For further information, please contact:

Anders Karlsson, CEO, Idogen AB

Phone: +46 (0)70 918 00 10

Email: anders.karlsson@idogen.com

Certified Adviser:
Vator Securities AB, Kungsgatan 34, SE-111 35 Stockholm,

Email: ca@vatorsec.se.

Tel: +46 (0)8-580 065 99

The information was submitted for publication, through the agency of the contact persons set out above, on August 25, 2022 at 08:02 CET.

The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.